Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $60 00 by Analysts at Needham & Company LLC themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective decreased by Robert W. Baird from $115.00 to $70.00 in a research note published on Tuesday morning, MarketBeat.com reports. Robert W. Baird currently has an outperform rating on the stock. Several other research analysts have also issued reports on APLS. The Goldman Sachs Group lifted […]
Apellis Pharmaceuticals (APLS) to Release Earnings on Monday theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target lifted by Robert W. Baird from $105.00 to $115.00 in a research note published on Monday, FlyOnTheWall reports. Other research analysts have also recently issued research reports about the company. HC Wainwright increased their target price on Apellis Pharmaceuticals from $87.00 to $100.00 in a […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Investment analysts at Zacks Research raised their Q2 2025 earnings estimates for Apellis Pharmaceuticals in a note issued to investors on Thursday, July 13th. Zacks Research analyst A. Chakraborty now forecasts that the company will post earnings of $0.41 per share for the quarter, up from their […]